|
 
|
 |
|
|
|
|
|
|
|
|
 |
Alexza Pharmaceuticals
[NASDAQ:
ALXA]
|
 |
|
|
|
Increasing ease, comfort and convenience for people living with acute and intermittent conditions by enhancing drug effectiveness and minimizing drug invasiveness - that’s what they do at emerging pharmaceutical company Alexza. Cofounded by biotechnology and drug delivery pioneer, Dr. Alejandro Zaffaroni, Alexza is focused on the development and commercialization of new products using the company’s proprietary Staccato™ Technology which vapourizes unformulated drug to form a condensation aerosol that allows for systematic delivery through deep inhalation. To date nearly 200 drug compounds have exhibited initial feasibility with the Staccato™ System technology.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
 |
|
|
|
|
Archemix
|
|
|
|
|
Archemix is a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, an emerging new class of potential therapeutic agents. Using Archemix’s processes for discovering aptamers, which are protected by its broad patent portfolio, Archemix is developing aptamer product candidates for rare hematological diseases. In addition, Archemix has licensed its intellectual property to third parties to develop their own aptamer product candidates in other areas. Currently, Archemix’s licensees are evaluating five different aptamer product candidates in human clinical trials; two in Phase 2 and three in Phase 1. Archemix has additional partnerships with several pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck Serono, Pfizer, Takeda, Eli Lilly and Isis Pharmaceuticals.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Argos Therapeutics
|
|
|
|
|
Creating a new generation of personalized cancer and infectious disease therapeutics that target the unique features of a patient’s disease by training the patient’s own immune system to recognize and attack the disease, Argos Therapeutics’ "Arcelis" technology uses RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. Argos has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Cardiac Dimensions
|
|
|
|
|
Cardiac Dimensions®, Inc., based in Kirkland, WA, is developing a minimally invasive implantable product to treat mitral valve regurgitation associated with congestive heart failure. This percutaneous approach to annuloplasty is accomplished by implanting a device in the great cardiac vein / coronary sinus via a catheter-based delivery system. The implant is designed to reshape the mitral annulus that surrounds the valve and reduce the mitral regurgitation. Lumira Capital co-led, with Johnson & Johnson Development Corp., the US$35.5MM Series D financing which closed Dec 17, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Cardiovascular Systems
[NASDAQ:
CSII]
|
|
|
|
|
Cardiovascular Systems Inc. (CSI), a medical device company based in St. Paul, Minnesota, develops and commercializes interventional technologies for the treatment of cardiovascular disease. The company’s goal is to provide physicians with safer, more effective tools to help the 8 million to 12 million Americans suffering from peripheral arterial disease (PAD) – blockages in the arteries of the leg – and the potential catastrophic risk of limb amputation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Ception Therapeutics
- Exited
|
|
|
|
|
Ception Therapeutics is an emerging pharmaceutical company focused on the discovery and development of novel products to address unmet needs in the areas of inflammatory, infectious and vascular diseases. The company’s pipeline includes a late stage anti-IL-5 monoclonal antibody in clinical development for eosinophilic esophagitis and other eosinophil mediated inflammatory indications. The company’s discovery pipeline includes a small molecule anti-TNF program, an anti-infective program, and a novel anti-thrombotic program. Lumira Capital invested in Ception in January, 2007. Cephalon Inc. announced a $100 million upfront deal in January 2009 for the option to purchase all of Ception's oustanding capital stock and excerised its option in March 2010, acquiring Ception for an additonal $250 million plus significant payments for future milstones.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Corus Pharma
- Exited
|
|
|
|
|
Corus develops generic drugs for novel patentable pulmonary indications - Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependant asthma. Lumira Capital fully exited when Corus Pharmaceuticals was acquired by Gilead in August 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Depomed
- Exited
[NASDAQ:
DEPO]
|
|
|
|
|
Reducing the side effects of pharmaceutical products without sacrificing efficacy - that’s what they do at Depomed, a specialty pharmaceutical company engaged in the development of pharmaceutical products, based on its Acuformtm oral drug delivery systems. During 2005, the FDA approved two products developed by Depomed, ProQuin XR, a once-daily formulation of the antibiotic drug ciprofl oxacin for uncomplicated urinary tract infections, and Glumetza, a once-daily metformin product for Type II diabetes. Lumira Capital led a PIPE in 2003 and fully exited in 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Guava Technologies
- Exited
|
|
|
|
|
Guava Technologies develops, manufactures and markets unique, high-impact cellular analysis systems for the life science research marketplace that enable scientists to do more experiments with fewer cells and less time - improving the efficiency and effectiveness of scientific research as well as drug development and discovery in research laboratories around the world. Guava provides highly miniaturized, hands-on, microliter-scaled systems that make commonly used, but important assays in cell-based analysis accessible at the benchtop. Guava's technology has broad applications to life science research, drug discovery, and biopharmaceutical production today, while also offering potential for use in clinical testing, blood processing, and predictive medicine, as well as other areas where single cell analysis is important. Guava Technologies was acquired for $22.6 million by Millipore Inc. in February, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
ISTA Pharmaceuticals
- Exited
[NASDAQ:
ISTA]
|
|
|
|
|
Helping people to see better, ISTA is a specialty pharmaceutical company that creates therapeutics for diseases and conditions of the eye. Since our PIPE in 2002, the company has successfully launched three products in the United States, creating significant value for shareholders. Lumira Capital fully exited in March 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
KAI Pharmaceuticals
|
|
|
|
|
KAI Pharmaceuticals is a biology-based product-driven drug discovery and development company with clinical and preclinical therapeutic programs for the acute treatment of ischemia and reperfusion injury and for diseases involving chronic regulation of angiogenesis. The company is applying its core expertise in the biology of specific protein kinase C (PKC) isozymes to develop highly specific activators and inhibitors of PKC isozymes for the treatment of a variety of human diseases. KAI recently completed a Phase I/II study of KAI-9803, a delta PKC inhibitor, to prevent reperfusion injury in patients undergoing angioplasty following acute myocardial infarction (AMI). The FDA has granted KAI-9803 Fast Track designation. KAI-1455, KAI’s development candidate for cytoprotection during ischemic procedures, entered clinical trials in early 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
MAKO Surgical
[NASDAQ:
MAKO]
|
|
|
|
|
MAKO Surgical Corp. is a medical device company that markets both its RIO Robotic-Arm Interactive Orthopedic system and its proprietary RESTORIS(r) implants for minimally invasive orthopedic knee procedures. The MAKO RIO System (RIO) is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee joint for the insertion and alignment of MAKO's resurfacing implants through a minimal incision. The FDA-cleared RIO system allows surgeons to provide a precise, consistently reproducible tissue-sparing, bone resurfacing procedure called MAKOplasty(r) to a large, yet underserved patient-specific population suffering from early to mid-stage osteoarthritic knee disease. MAKO went public in 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Morphotek
- Exited
|
|
|
|
|
Morphotek, Inc. is a biopharmaceutical company focused on the discovery and development of therapeutic monoclonal antibodies (mAbs) for the treatment of cancer, inflammatory and infectious diseases. Morphotek develops these antibodies through the use of its proprietary human antibody technologies, Human MORPHODOMA® and Libradoma™. Two of the company’s mAb programs are currently in clinical trials for the treatment of ovarian and pancreatic cancer with several others in preclinical development. Lumira Capital invested in 2006 and exited through an acquisition by Eisai in April 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
NVSS Corp. (formerly Alveolus)
- Exited
|
|
|
|
|
With the goal of enhancing the quality of life and reducing long term medical costs for people who suffer from pulmonary or gastrointestinal obstruction, Alveolus products are created by physicians, for physicians. The leading developer of next generation non-vascular interventional stent technology for use in the lungs, Alveolus is also in various stages of development of stents for use in the esophagus, colon, duodenum, pancreas, biliary tract and other ducts. Alveolus was acquired by Merit Medical Systems Inc. in February 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Pharmasset
[NASDAQ:
VRUS]
|
|
|
|
|
Committed to discovering, developing and commercializing novel drugs to treat viral infections, Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Pharmasset is currently developing three product candidates. R7128, an oral treatment for chronic HCV infection, is currently in a phase IIb study through a strategic collaboration with Roche in April 2009. PSI-7891, also for the treatment of HCV, entered the clinic in a phase IIa study in January 2010 and Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed two Phase 1 clinical studies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Renovis
- Exited
[NASDAQ:
RNVS]
|
|
|
|
|
Renovis is a public company developing technologies leading to the identification and discovery of novel validated targets and therapeutics for neurological diseases and psychiatric disorders. Lumira Capital exited in 2005 and 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Resonant Medical
- Exited
|
|
|
|
|
Committed to helping cancer centres advance patient care, Resonant Medical is a leader in the research, development and marketing of 3D ultrasound image-guided radiotherapy products designed to improve treatment planning, verification and delivery. The Clarity™ Platform accurately visualizes and corrects daily changes in tumor position, shape and size – launching a new era of 3D ultrasound (U/S) multimodality radiotherapy treatment planning and image guidance by allowing for better definition of planning tumor volumes more affordably and with or without PET or MRI. Resonant was acquired by Elekta in May of 2010 for $30 million in cash. Elekta develops sophisticated, state-of-theart
tools and treatment-planning systems for radiation therapy and radiosurgery.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Spinal Kinetics
|
|
|
|
|
Pioneering a new generation of artificial discs for the treating degenerative disc disease in the cervical and lumbar spine, Spinal Kinetics has developed unique technology designed to replicate the natural vertebral disc in its structure and physiologic range of motion in all planes, including axial compression. This more natural disc design allows for the disc to adjust itself to the anatomy and motion requirements of the spine.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
TransMolecular
|
|
|
|
|
TransMolecular is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies that promise to improve outcomes for cancer diseases that have inadequate pharmaceutical alternatives: gliomas, metastatic brain tumors, and other aggressive cancers with limited treatment options. The company is currently in Phase II trials of a proprietary agent, TM-601, that has shown promise in the treatment of high-grade glioma, a rapidly progressing, treatment-resistant form of brain cancer. A radiolabeled form of TM-601 ( I-TM-601) was approved by the FDA as an investigational drug in April 2002, was granted orphan drug status for patients with high-grade glioma, and has received Fast Track designation. A Phase I/II high-grade glioma clinical trial was successfully completed in 2004. A Phase II trial evaluating the effects of three or six weekly injections in patients with recurrent high-grade glioma is currently ongoing.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
U-Systems
|
|
|
|
|
U-Systems, Inc. designs, develops and markets innovative, cost-effective, ultrasound systems to assist the radiologist in detection of breast cancer. The company has built a leadership position in automated breast ultrasound imaging systems and has incorporated proprietary hardware and software technology into its FDA-cleared and CE-marked SomoVu™ Automated Breast Ultrasound System that provides cost-effective ultrasound imaging of the breast with technology that is especially effective for dense-breasted women.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Acorda Therapeutics
- Exited
[NASDAQ:
ACOR]
|
|
|
|
|
Acorda is a biopharmaceutical company developing therapies for treating multiple spinal cord injuries, multiple sclerosis and epilepsy. The company completed a successful IPO and announced positive results from its Phase III clinical trial of Fampridine-SR for improved walking ability for people with multiple sclerosis in 2006. Lumira Capital fully exited in September 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
NephroGenex
|
|
|
|
|
Working to overcome long standing obstacles for drug development to provide more effective treatments for renal disease, NephroGenex is a biotechnology company developing advanced treatments for kidney disease. The company is acquiring commercial rights to clinical-stage candidates that exhibit activity toward established renal pathology, and determining renal molecular profiles and biomarkers that identify patients that are likely to respond to therapy. The resulting molecular-based patient stratification can dramatically reduce the cost, time and risk of late stage clinical trials and improve the prospects for achieving significant treatment effects. The company is also applying renal molecular profiling to identify and validate novel molecular targets for the leading kidney diseases. The company’s lead product, Pyridorin for the treatment of diabetic nephropathy, has completed several Phase II studies.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Pathfinder Therapeutics
|
|
|
|
|
Pathfinder Therapeutics (PTI) is committed to developing an innovative, image-guided surgical system that will allow physicians to perform more efficient, accurate surgeries through image guided surgery and treatment through image guided technology that allows the complete treatment of a disease or disorder with no damage to the surrounding healthy tissue. The company’s current focus is on the development of a technology platform for image guided liver surgery.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Salu
- Exited
|
|
|
|
|
Physician founded and directed since 1997, SkinStore.com (wholly-owned by Salu) is among the leading health and beauty online retailers worldwide offering over 5,000 skin care, health and beauty products usually found only in doctors’ offices, spas and better department stores. Salu was acquired by Drugstore.com January 2010 for $36 million.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
TriVirix
|
|
|
|
|
An innovative full service contract manufacturer of electro-mechanical systems and devices to the medical, analytical, diagnostic and life science equipment industries, TriVirix helps companies develop, manufacture, service and support their electronic and electromechanical devices and instruments – allowing them to remain focused on their core technologies and strengths. Companies can also take advantage of TriVirix’s extensive regulatory knowledge and the company’s ISO 13485/FDA registered operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
 |
|
|
|
|
|
|
|
|
|
|
